MeiraGTx Holdings plc 8K

MeiraGTx reported strong Q2 2026 results driven by major strategic transactions, including acquiring full rights to bota-vec, securing up to $400 million from Oberland Capital, and advancing late-stage gene therapy programs with favorable regulatory designations and pivotal trial progress.

On August 13, 2026, MeiraGTx Holdings plc reported its second quarter 2026 financial and operational results, highlighting completion of the $25 million acquisition of all rights to botaretigene sparoparvovec (bota-vec) for X‑linked retinitis pigmentosa from Johnson & Johnson, receipt of FDA Breakthrough Therapy Designation and positive three‑year Phase 1 data for AAV2‑hAQP1 in radiation-induced xerostomia, entry into a strategic financing agreement with Oberland Capital for up to $400 million (including up to $375 million in non‑dilutive royalty-based funding and up to $25 million in equity), and a strengthened balance sheet via a $100 million equity financing and collaboration arrangements with Eli Lilly and Hologen/Reogen, alongside detailed quarterly financial results showing a swing to net income driven by significant collaboration and license revenues.

Filing Facts

CIK

1735438

Ticker

MGTX

Form

8K

Source Type

fda

Accession

0001104659-26-095491

Alert Tier

8